期刊
HEALTH AFFAIRS
卷 29, 期 3, 页码 530-536出版社
PROJECT HOPE
DOI: 10.1377/hlthaff.2009.0119
关键词
-
资金
- GlaxoSmithKline
- Pfizer
Value-based insurance design reduces patient copayments to encourage the use of health care services of high clinical value. As employers face constant pressure to control health care costs, this type of coverage has received much attention as a cost-savings device. This paper's examination of one value-based insurance design program found that the program led to reduced use of nondrug health care services, offsetting the costs associated with additional use of drugs encouraged by the program. The findings suggest that value-based insurance design programs do not increase total systemwide medical spending.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据